ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag clinical trials tuberculosis biotech business

2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Start It Up
Dan Cossins | Apr 1, 2013 | 8 min read
Young researchers who left the academic path to transform their bright ideas into thriving companies discuss their experiences, and how you can launch your own business.
Home-Base Biotech
Katherine Bagley | Jan 1, 2010 | 6 min read
By Katherine Bagley Home-Base Biotech African and international efforts are boosting the continent’s biotech industry—for now. Employees of Aspen Pharmaceutical Research Laboratories, which produce generic drugs including AIDS medicines, sort tablets in Port Elizabeth, South Africa. © AP Photo / John MCconnico As H1N1 spread from continent to continent in 2009, there was growing concern over the severity of swine
When Biotechs get Makeovers
Alison McCook(amccook@the-scientist.com) | Oct 9, 2005 | 9 min read
It was the beginning of 2002, and employees of Renovis, a biopharmaceutical company based in San Francisco had many reasons to celebrate.
Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017 | 10 min read
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.
The Little Cell That Could
Megan Scudellari | Jul 1, 2012 | 7 min read
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.
Pharmaceutical And Biotech Firms Taking On Drug-Resistant Microbes
Kathryn Brown | Jun 9, 1996 | 9 min read
Drug-Resistant Microbes As pesky pathogens continue to evolve, new technologies to combat them are emerging, spelling job opportunities for molecular biologists and chemists. OBSTINATE MICROBES: Margaret Rennels cites strains of pneumococcus resistence to two major drugs. At drug and biotech companies across the United States, scientists have set their sights on a most elusive target: drug-resistant microbes. Working in pharmaceutical- biotechnology partnerships, researchers are trying every

Run a Search

ADVERTISEMENT